Skip to main content
Premium Trial:

Request an Annual Quote

Anthrax Antimicrobial One Goal of Paradigm Genetics, VDDI Collaboration

NEW YORK, Feb. 26 - Paradigm Genetics and VDDI Pharmaceuticals will research and develop novel antibiotics for certain bacteria that may be used as bioterror agents, the companies said on Tuesday.

Terms of the deal call for Paradigm to supply its MetaVantage platform. VDDI, meanwhile, will provide samples of a new class of antimicrobials recently discovered at the University of Alabama.

VDDI acquired the rights to the antimicrobial compounds, which researchers at the school claim target an important enzyme responsible for keeping alive certain microbes, in this case gram-positive bugs like Anthrax.

The agreement also gives Paradigm the option to co-develop with VDDI certain compounds for antibiotic and anti-fungal applications for applications in human health and agrochemistry.

Financial details of the collaboration were not disclosed.

This deal was originally funded with the help of a $6 million Defense Advanced Research Projects Agency grant to the UAB Center for Biophysical Sciences and Engineering, VDDI said. Next month, the US Department of Defense is set to award VDDI a multi-year contract worth $23 million to research and develop antibiotics that treat Anthrax.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.